GeoVax Labs Statistics
Total Valuation
GeoVax Labs has a market cap or net worth of $4.70 million. The enterprise value is -$309,214.
Important Dates
The next estimated earnings date is Thursday, March 26, 2026, after market close.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GeoVax Labs has 2.63 million shares outstanding. The number of shares has increased by 374.84% in one year.
| Current Share Class | 2.63M |
| Shares Outstanding | 2.63M |
| Shares Change (YoY) | +374.84% |
| Shares Change (QoQ) | +32.08% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 6.43% |
| Float | 2.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.40 |
| Forward PS | n/a |
| PB Ratio | 0.43 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.57
| Current Ratio | 3.57 |
| Quick Ratio | 2.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -377.44% and return on invested capital (ROIC) is -238.07%.
| Return on Equity (ROE) | -377.44% |
| Return on Assets (ROA) | -178.93% |
| Return on Invested Capital (ROIC) | -238.07% |
| Return on Capital Employed (ROCE) | -520.51% |
| Weighted Average Cost of Capital (WACC) | 25.58% |
| Revenue Per Employee | $197,268 |
| Profits Per Employee | -$1.49M |
| Employee Count | 17 |
| Asset Turnover | 0.38 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.91% in the last 52 weeks. The beta is 3.88, so GeoVax Labs's price volatility has been higher than the market average.
| Beta (5Y) | 3.88 |
| 52-Week Price Change | -95.91% |
| 50-Day Moving Average | 2.91 |
| 200-Day Moving Average | 13.33 |
| Relative Strength Index (RSI) | 36.53 |
| Average Volume (20 Days) | 135,466 |
Short Selling Information
The latest short interest is 272,648, so 10.38% of the outstanding shares have been sold short.
| Short Interest | 272,648 |
| Short Previous Month | 321,661 |
| Short % of Shares Out | 10.38% |
| Short % of Float | 10.40% |
| Short Ratio (days to cover) | 1.54 |
Income Statement
In the last 12 months, GeoVax Labs had revenue of $3.35 million and -$25.31 million in losses. Loss per share was -$40.74.
| Revenue | 3.35M |
| Gross Profit | -19.38M |
| Operating Income | -25.54M |
| Pretax Income | -25.31M |
| Net Income | -25.31M |
| EBITDA | -25.47M |
| EBIT | -25.54M |
| Loss Per Share | -$40.74 |
Full Income StatementBalance Sheet
The company has $5.01 million in cash and n/a in debt, with a net cash position of $5.01 million or $1.91 per share.
| Cash & Cash Equivalents | 5.01M |
| Total Debt | n/a |
| Net Cash | 5.01M |
| Net Cash Per Share | $1.91 |
| Equity (Book Value) | 4.91M |
| Book Value Per Share | 4.13 |
| Working Capital | 4.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$24.27 million and capital expenditures -$27,612, giving a free cash flow of -$24.29 million.
| Operating Cash Flow | -24.27M |
| Capital Expenditures | -27,612 |
| Free Cash Flow | -24.29M |
| FCF Per Share | -$9.25 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -761.63% |
| Pretax Margin | -754.69% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GeoVax Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -374.84% |
| Shareholder Yield | -374.84% |
| Earnings Yield | -538.51% |
| FCF Yield | -516.90% |
Analyst Forecast
The average price target for GeoVax Labs is $200.00, which is 11,073.18% higher than the current price. The consensus rating is "Buy".
| Price Target | $200.00 |
| Price Target Difference | 11,073.18% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 12, 2026. It was a reverse split with a ratio of 1:25.
| Last Split Date | Jan 12, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
GeoVax Labs has an Altman Z-Score of -35.85 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -35.85 |
| Piotroski F-Score | 3 |
